Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)

John M. Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian GastmanGeorgina V. Long

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)'. Together they form a unique fingerprint.

Medicine and Dentistry